Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Lymphoma, Follicular: early-phase trial registry

A small indexed set (10 trials) with no open enrollment listed right now.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · none currently recruiting · #1,724 of 28,707 conditions by registered trial count

Lymphoma, Follicular: 10 US clinical trials tracked, none currently recruiting.

Lymphoma, Follicular is the subject of 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Triphase Research and Development III, running 1 of these trials.

Enrollment posture brief

Registry condition lymphoma-follicular

OPEN 0 | RECR 0% | LATE 1 | EARLY 9 | RANK #1724 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Acute Leukemia of Ambiguous 80%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%Lymphoma, Follicular (this)0%
Open-enrollment share among volume-matched conditions near Lymphoma, Follicular

Lymphoma, Follicular has no open enrollment in this registry pull (10 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lymphoma, Follicular on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lymphoma, Follicular is recruiting below its size-band peers.

    0 of 10 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Lymphoma, Follicular trials is spread across many organizations.

    Triphase Research and Development III accounts for 1 of 10 trials (10%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Most Lymphoma, Follicular trials plan to enrol fewer than 100 people.

    Median target enrolment is 66 among the 10 trials that report a genuine target (sentinel values excluded). 7 of those (70%) plan for fewer than 100 participants.

  4. Lymphoma, Follicular research is mostly interventional.

    10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 26Phase 31

Indexed trials (enrollment closed)

10 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2 90 participants

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Celgene

NCT06425302

ACTIVE NOT RECRUITING Phase 2 34 participants

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

Washington University School of Medicine

NCT05410418

COMPLETED Phase 3 315 participants

A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma

Archigen Biotech Limited

NCT02809053

COMPLETED Phase 2 279 participants

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

National Heart, Lung, and Blood Institute (NHLBI)

NCT02208037

COMPLETED Phase 1 190 participants

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

Pfizer

NCT01307267

COMPLETED Phase 2 66 participants

A Study of Enzastaurin in Participants With Follicular Lymphoma

Eli Lilly and Company

NCT00475644

COMPLETED Phase 1 64 participants

A Safety Study of SGN-CD19A for B-Cell Lymphoma

Seagen

NCT01786135

COMPLETED Phase 2 60 participants

A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma

SCRI Development Innovations

NCT00193492

COMPLETED Phase 2 55 participants

Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)

Medical College of Wisconsin

NCT00849147

COMPLETED Phase 1 32 participants

Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma

Triphase Research and Development III

NCT03682796

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 6
Phase 3 1

Named interventions

Most-linked intervention names on Lymphoma, Follicular records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Rituximab Drug
2 trials
Methotrexate (ARM with Bortezomib) Drug
1 trials
Methotrexate (ARM with Maraviroc) Drug
1 trials
Tacrolimus (ARM with MMF and Cyclophosphamide) Drug
1 trials
Tacrolimus (ARM with Methotrexate) Drug
1 trials
TRPH-222 Drug
1 trials
PF-05082566 Drug
1 trials
Enzastaurin Drug
1 trials

US sites by state

Facility locations filed on Lymphoma, Follicular trials. A trial with sites in several states counts in each.

California 7 trials
Florida 6 trials
Georgia 5 trials
Pennsylvania 4 trials
Tennessee 3 trials
Ohio 3 trials
New York 3 trials
Missouri 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lymphoma, Follicular page

10 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoma, Follicular condition card totals 10 registered trials; most-linked intervention Rituximab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.